PlexBio Co (ROCO:6572) Current Deferred Revenue: NT$0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6572 PlexBio Co Ltd ROCO:6572
67 GF Score
Price NT$7.83
GF Value NT$10.41
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is PlexBio Co Current Deferred Revenue?

PlexBio Co ROCO:6572 -0.25% 67 Current Deferred Revenue is NT$0.0 Mil as of Jun. 2026. GuruFocus rates ROCO:6572 with a GF Score™ of 67/100 and a GF Value™ of NT$10.41 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

PlexBio Co's current deferred revenue for the quarter that ended in Jun. 2026 was NT$0.0 Mil.

PlexBio Co Current Deferred Revenue Related Terms

PlexBio Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for PlexBio Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PlexBio Co Current Deferred Revenue Chart

PlexBio Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PlexBio Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6572
67GF Score
PlexBio Co Ltd ROCO:6572
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0.0 Mil mean?
PlexBio Co (ROCO:6572) has a Current Deferred Revenue of NT$0.0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on PlexBio Co and its competitors.
Is PlexBio Co's Current Deferred Revenue too high?
PlexBio Co's current Current Deferred Revenue is NT$0.0 Mil. Overall, PlexBio Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PlexBio Co's Current Deferred Revenue compare to ABT and SYK?
PlexBio Co's Current Deferred Revenue of NT$0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on PlexBio Co and its competitors. PlexBio Co's current Current Deferred Revenue is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PlexBio Co stock overvalued right now?
Based on GuruFocus' analysis, PlexBio Co (ROCO:6572) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$10.41, compared to a current price of NT$7.83 — trading 24.8% below its estimated fair value. The current Current Deferred Revenue is NT$0.0 Mil. PlexBio Co's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For PlexBio Co (ROCO:6572), the current Current Deferred Revenue is NT$0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PlexBio Co (ROCO:6572) Overvalued in 2026?

Based on GuruFocus' analysis, PlexBio Co stock appears to be undervalued. The current stock price of NT$7.83 is trading 24.8% below its estimated GF Value™ of NT$10.41. GuruFocus considers PlexBio Co to be Modestly Undervalued.

Key valuation signals for ROCO:6572:

  • Current Deferred Revenue: NT$0.0 Mil
  • GF Value™: NT$10.41 vs. price of NT$7.83 (24.8% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PlexBio Co Business Description

Address 6F-1, Number 351, Yangguang Street, Neihu District, Taipei, TWN, 11491
PlexBio Co Ltd is a Taiwan based company involved in designing, developing and manufacturing IVD products and instrumentations. Its products are used in companion diagnostic panel, early cancer detection screening, prenatal diagnostics and for food and safety testing.
67GF Score

Get the complete analysis for ROCO:6572

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$7.83
Price
NT$10.41
GF Value